Hui et al. [139] performed scRNA-seq on tumor-bearing mice deficient in APOE and noticed a decrease in M2-like C1QC+ and CCR2+ TAMs, suggesting that targeting APOE+ macrophages could be a novel strategy to combine with ICB for cancer treatment. This evidence concerns the gene APOE and neoplasm.